Evidence map›Paper›PMID 40524006›Full record

ArticleEuropean journal of pediatrics2025

Cytogenetic anomalies are the predominant genetic alteration in children with nonfamilial tall stature: a comparative study with familial cases.

Katerina Gregorova, Lukas Plachy, Petra Dusatkova, Klara Maratova, Julia Martinkova, Jana Drabova, Vit Neuman, Stanislava Kolouskova, Marta Snajderova, Barbora Obermannova and 3 more

Abstract readComparative Study
In one paragraph

Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Katerina GregorovaDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.ORCID http://orcid.org/0009-0006-4814-5446
Lukas PlachyDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.ORCID http://orcid.org/0000-0003-3382-3508
Petra DusatkovaDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic. petra.dusatkova@lfmotol.cuni.cz.ORCID http://orcid.org/0000-0002-8647-9088
Klara MaratovaDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.ORCID http://orcid.org/0000-0001-9671-8284
Julia MartinkovaDepartment of Biology and Medical Genetics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.ORCID http://orcid.org/0000-0001-8872-0202
Jana DrabovaDepartment of Biology and Medical Genetics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.ORCID http://orcid.org/0000-0002-5821-4744
Vit NeumanDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.ORCID http://orcid.org/0000-0002-1745-5285
Stanislava KolouskovaDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.
Marta SnajderovaDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.
Barbora ObermannovaDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.ORCID http://orcid.org/0009-0002-5126-7349
Jan LeblDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.ORCID http://orcid.org/0000-0002-3365-5375
Zdenek SumnikDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.ORCID http://orcid.org/0000-0002-6462-6462
Stepanka PruhovaDepartment of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic.ORCID http://orcid.org/0000-0001-8019-8026

Funding

Ministerstvo Zdravotnictví Ceské Republiky NU21-07-00335
6 · The paper itself

Abstract

The purpose of this study is to elucidate the genetic causes and phenotypic presentation of nonfamilial tall stature (nFTS) and to compare these findings with those of familial tall stature (FTS) from the same population that was previously studied. Children with nFTS (defined as a height >  + 2 SDs with both parents' heights <  + 2 SDs) underwent endocrine and anthropometric examinations and genetic testing (karyotyping, SHOX gene dosage analysis and next-generation sequencing of 786 growth-associated genes). Exome sequencing was performed in patients with negative genetic results and a height >  + 3 SDs. A total of 55 children with nFTS were enrolled. The median height was + 2.8 SD (2.4-3.2 SD), and the median midparental height was + 0.7 SD (0.4-0.9 SD). Genetic causes of tall stature were identified in 6/55 (11%) children. Specifically, four children had gonosomal aneuploidy (47,XXY [2x], 47,XXX, 48,XXXX), one had a heterozygous complex rearrangement including SHOX gene duplication, and one carried a pathogenic variant in the TGFBR2 gene leading to Loeys-Dietz syndrome. A genetic cause of tall stature was significantly less common in nFTS (11%) than in our previously published cohort with FTS (32%). Conclusion: Cytogenetic abnormalities were the predominant genetic alteration identified in children with nFTS, confirming the justification of karyotype analysis in this cohort. The probability of genetic alterations was greater in children with FTS than in those with nFTS. Our findings suggest that the current guidelines for complex investigation are efficient for children with nFTS but need revision in children with FTS. What is known - what is new • Although tall stature is generally considered beneficial, it can be associated with health risks which need to be recognized in time. Tall stature without intellectual impairment is usually considered to be polygenic. • However, the cause of familial tall stature was monogenic more often than it was thought previously. • Children with non-familial and apparently non-syndromic tall stature have never been systematically investigated. • Monogenic causes of non-familial tall stature were observed in 11% of patients, including a participant with Loeys-Dietz syndrome.

Indexed as

Body HeightChromosome AberrationsGrowth DisordersAdolescentChildChild, PreschoolExome SequencingFemaleGenetic TestingHumansKaryotypingMalePhenotypeShort Stature Homeobox ProteinShort Stature Homeobox ProteinSHOX protein, humanGenetics of tall statureGrowthNext-generation sequencingNon-familial tall statureTall stature

Identifiers

PMID40524006
PMCPMC12170751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.